Navigation Links
Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
Date:10/27/2008

ertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section in Item 1 of the Form 10-KSB we filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar Therapeutics to Webcast R&D Day on November 12th
2. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
3. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
4. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
5. CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
6. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
7. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
10. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
11. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... development places National Stem Cell in the sector for Anti-aging, ... and one of the ... Today, MOUNTAINSIDE, N.J., Oct. 25 National Stem,Cell Holding, ... is currently in final stage negotiations to exclusively license one ...
... Mass., Oct. 25 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... a,conference call at 8:00 a.m. ET on Thursday, ... third-quarter 2007 financial and,operational results and upcoming activities. ... available on the webcast. Prior to the,conference call ...
... Glycominds Ltd., a,bio-diagnostics company specializing in glycan ... and cancer, announced today,entering into a research agreement ... cancer center to develop a new diagnostics blood ... to work with FCCC on this project," stated ...
Cached Biology Technology:National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications 2Millennium to Webcast Third-Quarter 2007 Financial and Operational Results 2Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests 2
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market ... it is important to upgrade biometric solutions to the ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for a ... for this $50 million capital project is part of a ... The medical education building will be located ... adjacent to 525@vine in Wake Forest Innovation Quarter. Construction will ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... -- Reseachers at The Ohio State University have ... an effective method for preserving the important genetic diversity ... geranium, are some of the most popular flowers the ... Society listed more than 3,000 varieties of geranium in ...
... -- Two common dietary molecules found in legumes ... effects of radiation, researchers from the University of ... both human skin cells and a skin cancer-prone ... the damaging radiation found in sunlight, the team ...
... scientists today announced the results of a systematic effort ... worlds leading cause of cancer deaths. Appearing in the ... the research provides a comprehensive view of the abnormal ... 50 genomic regions that are frequently gained or lost ...
Cached Biology News:'TRAP' preserves genetic properties of popular geranium 2Antioxidants could provide all-purpose radiation protection 2Antioxidants could provide all-purpose radiation protection 3Genome study charts genetic landscape of lung cancer 2Genome study charts genetic landscape of lung cancer 3
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Mouse monoclonal [3B6] to HSV1 + HSV2 ICP5 Major Capsid Protein ( Abpromise for all tested applications)....
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Biology Products: